These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 36941816)

  • 1. Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis (Black Fungus): A Review.
    Upadhayay P; Bansal K; Goyal A
    Curr Pharm Biotechnol; 2023; 24(13):1645-1656. PubMed ID: 36941816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.
    Azhar A; Khan WH; Khan PA; Alhosaini K; Owais M; Ahmad A
    J Infect Public Health; 2022 Apr; 15(4):466-479. PubMed ID: 35216920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucormycosis, past and present: a comprehensive review.
    Gupta I; Baranwal P; Singh G; Gupta V
    Future Microbiol; 2023 Feb; 18():217-234. PubMed ID: 36970978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucormycosis: An opportunistic pathogen during COVID-19.
    Mahalaxmi I; Jayaramayya K; Venkatesan D; Subramaniam MD; Renu K; Vijayakumar P; Narayanasamy A; Gopalakrishnan AV; Kumar NS; Sivaprakash P; Sambasiva Rao KRS; Vellingiri B
    Environ Res; 2021 Oct; 201():111643. PubMed ID: 34237335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.
    Sharma A; Goel A
    Folia Microbiol (Praha); 2022 Jun; 67(3):363-387. PubMed ID: 35220559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.
    Gurunathan S; Lee AR; Kim JH
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.
    Monika P; Chandraprabha MN
    Mol Biol Rep; 2022 Jun; 49(6):4977-4988. PubMed ID: 35107737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.
    Sharma N; Wani SN; Behl T; Singh S; Zahoor I; Sehgal A; Bhatia S; Al-Harrasi A; Aleya L; Bungau S
    Environ Sci Pollut Res Int; 2023 Jan; 30(4):9164-9183. PubMed ID: 36454526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.
    Gupta G; S R; Singh Y; Thangavelu L; Singh SK; Dureja H; Chellappan DK; Dua K
    Drug Dev Res; 2021 Nov; 82(7):880-882. PubMed ID: 34323298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 and the alarming rise of "black fungus" (mucormycosis) infection.
    Khajotia R
    Pan Afr Med J; 2022; 41():318. PubMed ID: 35865834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
    Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
    Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucormycosis, The Deadly New Worry to COVID-19 Pandemic.
    Kamrul-Hasan AB; Selim S
    Mymensingh Med J; 2021 Jul; 30(3):874-880. PubMed ID: 34226483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surge of mucormycosis during the COVID-19 pandemic.
    Dam P; Cardoso MH; Mandal S; Franco OL; Sağıroğlu P; Polat OA; Kokoglu K; Mondal R; Mandal AK; Ocsoy I
    Travel Med Infect Dis; 2023; 52():102557. PubMed ID: 36805033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucormycosis in COVID-19 pandemic: Risk factors and linkages.
    Kumar M; Sarma DK; Shubham S; Kumawat M; Verma V; Singh B; Nagpal R; Tiwari RR
    Curr Res Microb Sci; 2021 Dec; 2():100057. PubMed ID: 34396355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of Profile of Mucormycosis During the Second Wave of COVID-19 in a Tertiary Care Hospital.
    Kamath S; Kumar M; Sarkar N; Ahmed T; Sunder A
    Cureus; 2022 Jan; 14(1):e21054. PubMed ID: 35155019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mucormycosis in the time of COVID-19: risks and challenges].
    Seidel D; Sal E; Nacov JA; Cornely OA; Kurzai O
    Dtsch Med Wochenschr; 2024 May; 149(10):569-578. PubMed ID: 38657596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India.
    Joshi S; Telang R; Tambe M; Havaldar R; Sane M; Shaikh A; Roy C; Yathati K; Sonawale S; Borkar R; Magar R; Bhitkar H; Shitole S; Nakate L; Kudrimoti J; Mave V
    Emerg Infect Dis; 2022 Jan; 28(1):1-8. PubMed ID: 34586055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
    Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID19 associated mucormycosis: A review.
    Palanisamy PR; Elango D
    J Family Med Prim Care; 2022 Feb; 11(2):418-423. PubMed ID: 35360784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.